Xtl Biopharmaceuticals annual r&d spending
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Xtl Biopharmaceuticals R&D Spending Growth & History (XTLB)
Xtl Biopharmaceuticals's r&d spending was $28,000 for fiscal 2025.
View full Xtl Biopharmaceuticals company overviewXtl Biopharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $28,000 | −$70,000 | −71.43% |
| 2024 | 2024-12-31 | $98,000 | $67,000 | +216.13% |
| 2023 | 2023-12-31 | $31,000 | $1,000 | +3.33% |
| 2022 | 2022-12-31 | $30,000 | $0 | 0.00% |
| 2021 | 2021-12-31 | $30,000 | −$8,000 | −21.05% |
| 2020 | 2020-12-31 | $38,000 | $3,000 | +8.57% |
| 2019 | 2019-12-31 | $35,000 | −$3,000 | −7.89% |
| 2018 | 2018-12-31 | $38,000 | −$5,000 | −11.63% |
| 2017 | 2017-12-31 | $43,000 | −$400,000 | −90.29% |
| 2016 | 2016-12-31 | $443,000 | −$135,000 | −23.36% |
| 2015 | 2015-12-31 | $578,000 | — | — |
Xtl Biopharmaceuticals quarterly r&d spending
Q2.20
Q2.21
Q2.22
Q4.24
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | $32,000 | — | — |
| Q2 2022 | 2022-06-30 | $15,000 | $9,000 | +150.00% |
| Q2 2021 | 2021-06-30 | $6,000 | −$5,000 | −45.45% |
| Q2 2020 | 2020-06-30 | $11,000 | — | — |
Xtl Biopharmaceuticals r&d spending trends
Over the last five fiscal years, Xtl Biopharmaceuticals's r&d spending decreased from $38,000 to $28,000, a change of −$10,000. The latest reported quarter, Q4 2024, shows $32,000.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xtl Biopharmaceuticals source filings ↗